Everything Jim Cramer said about the stock market on ‘Mad Money,’ including climate change, Microsoft sustainability, GW Pharma CBD sales

CNBC’s Jim Cramer stressed why it’s important for American business to become more environmentally conscious. The “Mad Money” host sat down with the CEO and CFO of Microsoft to get a deeper look in to the software giant’s ambitious sustainability plan. Later in the show he got insight into CBD medicine sales with the head of British pharmaceutical company GW Pharmaceuticals.

Microsoft is on a mission to become carbon negative in the next decade, and CNBC’s Jim Cramer thinks the ambitious plan has some teeth to it.

“I think they can do it because, remember, they are a powerful force — maybe the most powerful, especially when it comes to data centers, of almost any company on Earth,” the “Mad Money” host said about the new imitative. “So I think they can make an impact. I think this is real. This is not greenwash.”

The science is clear that environmental sustainability must factor in a corporation’s growth plans, or the capitalist and economic system the U.S. enjoys “will fundamentally be in jeopardy,” Microsoft CEO Satya Nadella told CNBC.

“The corporation’s purpose is to find profitable solutions to the problems of people and planet,” he said in a sit down with Cramer, citing author and University of Oxford business professor Colin Mayer. “‘Profitable’ is the key word, but ‘problems’ is the other key word for people and planet.”

The comments came after Microsoft, the world’s largest software company, announced an ambitious green plan intended to eliminate its carbon footprint and remove the amount of carbon it has emitted over the decades.

Preliminary sales figures for the first cannabis-based medicine in the United States are in and they’re telling a bullish story, according to GW Pharmaceuticals CEO Justin Gover.

Epidiolex, which contains cannabidiol to treat severe forms of epilepsy, brought in $104 million in net sales in the fourth quarter and a total of $296 million in 2019 across the globe, the British pharmaceutical company preannounced for its quarterly and full-year performances.

“It’s an incredible launch year for any medication [that] I think proves that this kind of medicine is really making a difference to patients,” Gover told Cramer in an interview. “It shows real value to the health-care system, and it sets us up, I think, in a very nice way for what should be another great year for us in 2020.”

In Cramer’s lightning round, the “Mad Money” host gave callers his thoughts about their favorite stock picks of the day in rapid speed.

JD.com: “We don’t need JD … because we’ve got Alibaba. Now they’re both up a lot, but I like Alibaba very much.”

Adverum Biotechnologies: “Well look, this is the kind of speculative I like and I encourage. I encourage this kind of speculation on Mad Money because as long as you don’t put too much money in it, maybe this is the home run. Don’t put too much money in it and it can work.”

Disclaimer

Disclosure: Cramer’s charitable trust owns shares of Microsoft.